SUNAKAWA YU 砂川優

… Alternative Names

砂川優スナカワユウ

Less

Researcher Number	10458515
Other IDs
Affiliation (Current)	2025: 聖マリアンナ医科大学, 医学部, 教授 2025: 昭和医科大学, 医学部, 兼任講師
Affiliation (based on the past Project Information) *help	2023: 聖マリアンナ医科大学, 医学部, 教授
Review Section/Research Field	Except Principal Investigator Basic Section 58030:Hygiene and public health-related: excluding laboratory approach
Keywords	Except Principal Investigator 深層学習 / 機械学習 / 腸内細菌叢 / 免疫チェックポイント阻害薬 / 治療効果予測

腸内細菌叢による免疫チェックポイント阻害薬の効果予測モデルの開発とパッケージ構築
- Principal Investigator
  
  井上永介
- Project Period (FY)
  2023 – 2025
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 58030:Hygiene and public health-related: excluding laboratory approach
- Research Institution
  Showa University

All 2024 2023

All Journal Article Presentation

[Journal Article] Tumor Response Predicts Survival Time of Nivolumab Monotherapy for Advanced Gastric Cancer: A Subgroup Analysis of the DELIVER Trial (JACCRO GC-08)2024
- Author(s)
  Sunakawa Yu、Sakamoto Yasuhiro、Kawabata Ryohei、Ishiguro Atsushi、Akamaru Yusuke、Kito Yosuke、Takahashi Masazumi、Matsuyama Jin、Yabusaki Hiroshi、Makiyama Akitaka、Suzuki Takahisa、Tsuda Masahiro、Yasui Hisateru、Hihara Jun、Takeno Atsushi、Inoue Eisuke、Ichikawa Wataru、Fujii Masashi
- Journal Title
  
  The Oncologist
  
  Volume: - Issue: 8 Pages: e997-e1002
- DOI
  10.1093/oncolo/oyae056
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23K09700
[Journal Article] Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer2024
- Author(s)
  Sunakawa Yu, Kuboki Yasutoshi et al.
- Journal Title
  
  Targeted Oncology
  
  Volume: 19 Issue: 1 Pages: 59-69
- DOI
  10.1007/s11523-023-01027-8
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23K09700
[Journal Article] The BEETS (JACCRO CC-18) trial: an observational and translational study of BRAF-mutated metastatic colorectal cancer2023
- Author(s)
  Inagaki Chiaki、Matoba Ryo、Yuki Satoshi、Shiozawa Manabu、Tsuji Akihito、Inoue Eisuke、Muro Kei、Ichikawa Wataru、Fujii Masashi、Sunakawa Yu
- Journal Title
  
  Future Oncology
  
  Volume: 19 Issue: 17 Pages: 1165-1174
- DOI
  10.2217/fon-2023-0209
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21K07866, KAKENHI-PROJECT-23K09700
[Journal Article] Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial2023
- Author(s)
  Kawakami Hisato、Sunakawa Yu、Inoue Eisuke、et al.
- Journal Title
  
  European Journal of Cancer
  
  Volume: 184 Pages: 10-20
- DOI
  10.1016/j.ejca.2023.02.003
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21K07866, KAKENHI-PROJECT-23K09700
[Presentation] A phase II trial of CapeOX plus nivolumab for early relapsed HER2-negative gastric cancer (JACCRO GC-11: FirSTAR trial).2024
- Author(s)
  Hiroyuki Arai, Eisuke Inoue, Masanori Terashima, Eishi Baba, Nobuhisa Matsuhashi, Kei Muro, Toshifumi Yamaguchi, Satoshi Yuki, Wataru Ichikawa, Masashi Fujii, and Yu Sunakawa
- Organizer
  ASCO-GI 2024
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-23K09700
[Presentation] Survival analysis by tumor response of nivolumab treatment in previously treated advanced gastric cancer from the DELIVER trial (JACCRO GC-08).2023
- Author(s)
  Yu Sunakawa, Yasuhiro Sakamoto, Ryohei Kawabata, Atsushi Ishiguro, Yusuke Akamaru, Yosuke Kito, Masazumi Takahashi, Jin Matsuyama, Hiroshi Yabusaki, Akitaka Makiyama, Takahisa Suzuki, Masahiro Tsuda, Hisateru Yasui, Jun Hihara, Atsushi Takeno, Eisuke Inoue, Wataru Ichikawa, and Masashi Fujii
- Organizer
  ASCO2023
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-23K09700

1. 井上永介 (50528338)

# of Collaborated Projects: 1 results

# of Collaborated Products: 5 results
2. SATOU Shinji

# of Collaborated Projects: 0 results

# of Collaborated Products: 2 results
3. 佐藤聡美

# of Collaborated Projects: 0 results

# of Collaborated Products: 2 results

SUNAKAWA YU 砂川優

砂川優スナカワユウ

Research Projects

Research Products

Co-Researchers

腸内細菌叢による免疫チェックポイント阻害薬の効果予測モデルの開発とパッケージ構築

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

[Journal Article] Tumor Response Predicts Survival Time of Nivolumab Monotherapy for Advanced Gastric Cancer: A Subgroup Analysis of the DELIVER Trial (JACCRO GC-08)2024

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer2024

Author(s)

Journal Title

DOI

Data Source

[Journal Article] The BEETS (JACCRO CC-18) trial: an observational and translational study of BRAF-mutated metastatic colorectal cancer2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial2023

Author(s)

Journal Title

DOI

Data Source

[Presentation] A phase II trial of CapeOX plus nivolumab for early relapsed HER2-negative gastric cancer (JACCRO GC-11: FirSTAR trial).2024

Author(s)

Organizer

Data Source

[Presentation] Survival analysis by tumor response of nivolumab treatment in previously treated advanced gastric cancer from the DELIVER trial (JACCRO GC-08).2023

Author(s)

Organizer

Data Source

SUNAKAWA YU 砂川 優

砂川 優 スナカワ ユウ

Research Projects

Research Products

Co-Researchers

腸内細菌叢による免疫チェックポイント阻害薬の効果予測モデルの開発とパッケージ構築

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

[Journal Article] Tumor Response Predicts Survival Time of Nivolumab Monotherapy for Advanced Gastric Cancer: A Subgroup Analysis of the DELIVER Trial (JACCRO GC-08)2024

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer2024

Author(s)

Journal Title

DOI

Data Source

[Journal Article] The BEETS (JACCRO CC-18) trial: an observational and translational study of BRAF-mutated metastatic colorectal cancer2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial2023

Author(s)

Journal Title

DOI

Data Source

[Presentation] A phase II trial of CapeOX plus nivolumab for early relapsed HER2-negative gastric cancer (JACCRO GC-11: FirSTAR trial).2024

Author(s)

Organizer

Data Source

[Presentation] Survival analysis by tumor response of nivolumab treatment in previously treated advanced gastric cancer from the DELIVER trial (JACCRO GC-08).2023

Author(s)

Organizer

Data Source

SUNAKAWA YU 砂川優

砂川優スナカワユウ